Rieko Watanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rieko Watanabe has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Atsushi Motegi
2 shared publicationsAtsushi Takise
2 shared publications- Akira Ono
Shizuoka Cancer Center, Shizuoka, Japan
1 shared publication - Asuka Tsuya
Shizuoka Cancer Center
1 shared publication Harunao Iizuka
Maebashi Red Cross Hospital
1 shared publication- Haruyasu Murakami
Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan
1 shared publication
Latest Publications
- 7 April 2015
- Published by Springer Nature in Investigational New Drugs
- Vol. 33 (3) , 755-760
The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients
Background Central nervous system (CNS) metastases caused by small-cell lung cancer (SCLC) are incurable and therefore fatal. Although such metastases are usually treated with chemotherapy or radiotherapy, their sensitivity to these treatment measures is unclear. Amrubicin appears to be a promising agent for relapsed SCLC, but its effectiveness in CNS metastases originating from SCLC is unknown. Methods Between April 2002 and December 2009, 110 SCLC patients with CNS metastasis were treated at Shizuoka Cancer Center. Of these, we retrospectively reviewed 8 consecutive cases with CNS metastases originating from relapsed SCLC that were treated with amrubicin as a second-line therapy. Results We recorded three sensitive relapses and five refractory cases. Amrubicin yielded a CNS response rate of 50 % (2 partial responses and 2 complete response; 95 % CI, 21.5–78.5 %) and the disease control rate for CNS lesions was 87.5 % (95 % CI, 52.9–97.8 %). All of the sensitive relapse patients achieved a partial response. The median time to progression for CNS metastases was 150.5 days (95 % CI, 9–171 days), and the median survival time from the start of amrubicin administration was 230.5 days (95 % CI, 89–619 days). We also report a dramatic improvement in one patient’s radiological result of intramedullary spinal cord metastasis and alleviation of her symptoms following amrubicin monotherapy including this case series. Conclusions The results of this study suggest that amrubicin is active in patients with CNS metastases originating from SCLC.
- 7 April 2015
- Published by Springer Nature in Investigational New Drugs
- Vol. 33 (3) , 755-760
The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients
Background Central nervous system (CNS) metastases caused by small-cell lung cancer (SCLC) are incurable and therefore fatal. Although such metastases are usually treated with chemotherapy or radiotherapy, their sensitivity to these treatment measures is unclear. Amrubicin appears to be a promising agent for relapsed SCLC, but its effectiveness in CNS metastases originating from SCLC is unknown. Methods Between April 2002 and December 2009, 110 SCLC patients with CNS metastasis were treated at Shizuoka Cancer Center. Of these, we retrospectively reviewed 8 consecutive cases with CNS metastases originating from relapsed SCLC that were treated with amrubicin as a second-line therapy. Results We recorded three sensitive relapses and five refractory cases. Amrubicin yielded a CNS response rate of 50 % (2 partial responses and 2 complete response; 95 % CI, 21.5–78.5 %) and the disease control rate for CNS lesions was 87.5 % (95 % CI, 52.9–97.8 %). All of the sensitive relapse patients achieved a partial response. The median time to progression for CNS metastases was 150.5 days (95 % CI, 9–171 days), and the median survival time from the start of amrubicin administration was 230.5 days (95 % CI, 89–619 days). We also report a dramatic improvement in one patient’s radiological result of intramedullary spinal cord metastasis and alleviation of her symptoms following amrubicin monotherapy including this case series. Conclusions The results of this study suggest that amrubicin is active in patients with CNS metastases originating from SCLC.
- 18 August 2006
- Published by Springer Nature in Radiation Medicine
- Vol. 24 (6) , 456-458
Intense accumulation of gallium-67 citrate in pancreatic endocrine tumor
We report intense accumulation of gallium-67 (Ga-67) citrate in a pancreatic endocrine tumor. A 69-year-old woman was admitted because of cough, fever, and weight loss. An abdominal enhanced computed tomography (CT) scan revealed a large tumor located between the liver and pancreas as well as swollen paraaortic lymph nodes. Whole-body scintigraphy with Ga-67 revealed intense accumulation in the upper abdomen corresponding to the mass, as well as in the midabdomen and the mediastinal lesion. Percutaneous needle biopsy was performed, and the diagnosis was adenocarcinoma of the pancreas. The patient's condition deteriorated, and she died 2 months after admission. The pathological examination at autopsy revealed a pancreatic endocrine tumor. No report has described findings of Ga-67 citrate scintigraphy of pancreatic endocrine tumors. Pancreatic endocrine tumor should be included in a differential diagnosis when such scintigraphic findings are encountered.
- 18 August 2006
- Published by Springer Nature in Radiation Medicine
- Vol. 24 (6) , 456-458
Intense accumulation of gallium-67 citrate in pancreatic endocrine tumor
We report intense accumulation of gallium-67 (Ga-67) citrate in a pancreatic endocrine tumor. A 69-year-old woman was admitted because of cough, fever, and weight loss. An abdominal enhanced computed tomography (CT) scan revealed a large tumor located between the liver and pancreas as well as swollen paraaortic lymph nodes. Whole-body scintigraphy with Ga-67 revealed intense accumulation in the upper abdomen corresponding to the mass, as well as in the midabdomen and the mediastinal lesion. Percutaneous needle biopsy was performed, and the diagnosis was adenocarcinoma of the pancreas. The patient's condition deteriorated, and she died 2 months after admission. The pathological examination at autopsy revealed a pancreatic endocrine tumor. No report has described findings of Ga-67 citrate scintigraphy of pancreatic endocrine tumors. Pancreatic endocrine tumor should be included in a differential diagnosis when such scintigraphic findings are encountered.